MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA

Clinical trials for MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA explained in plain language.

Never miss a new study

Get alerted when new MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA trials appear

Sign up with your email to follow new studies for MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

New drug trial targets scarring bone marrow disease

Disease control Ongoing

This study is testing if a drug called elotuzumab can help control myelofibrosis, a rare blood cancer that causes bone marrow scarring. The trial will involve about 15 adults with a specific genetic change (JAK2 mutation) who are not candidates for standard JAK inhibitor therapy.…

Matched conditions: MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA

Get alerted when new MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA trials appear

New drug trial targets scarring bone marrow disease